Xenon Pharmaceuticals Inc.

91 articles with Xenon Pharmaceuticals Inc.

• Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences - Nov 13, 2020

  11/13/2020

  Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following virtual investor conferences

• Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/5/2020

  Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, reported financial results for its third quarter ended September 30, 2020 and provided a corporate update.

• Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

  11/2/2020

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its third quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, November 5, 2020.

• Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-End

  10/8/2020

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today provided regulatory updates on its proprietary pediatric neurology program, XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE)

• Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy

  10/8/2020

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE) today provided an update on the ongoing collaboration for the clinical development of NBI-921352, previously known as XEN901

• Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer

  8/17/2020

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced today the appointment of Dr. Chris Von Seggern as Chief Commercial Officer, effective immediately. In this newly created role, Dr. Von Seggern will report to Dr. Simon Pimstone, Xenon’s Chief Executive Officer, and oversee the commercial strategy and execution for Xenon’s neurology-focused portfolio of therapeutics. Dr. Pimstone state

• Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/6/2020

  Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, reported its financial results for second quarter ended June 30, 2020 and provided a corporate update.

• Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences - Aug 04, 2020

  8/4/2020

  Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following virtual investor conferences

• Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

  7/30/2020

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its second quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, August 6, 2020. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update. To participat

• Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

  6/1/2020

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced today that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 pm Eastern time.

• Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

  5/21/2020

  Progress Reported in Both Proprietary and Partnered Neurology Clinical Programs  Additional FDA Feedback Supports Commencement of XEN496 Phase 3 Clinical Trial in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 21, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported its financial results for first quarter ended March 31, 2020 and provided a corporate update. Dr. Simon Pimstone, Xe

• Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Provide Corporate Update

  5/14/2020

  Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced that it will report its first quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, May 21, 2020.

• Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19

  3/31/2020

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update in the context of the developing situation with the COVID-19 pandemic.

• Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  3/26/2020

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 63,200 share options.

• Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate Update

  3/9/2020

  Xenon’s Robust Neurology Pipeline of Proprietary and Partnered Programs Advances with Multiple Important Milestone Opportunities Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 09, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2019 and provided a corporate update. Dr. Simon Pimstone, Xenon’s Chief Executive Offi

• Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2019 Financial Results and Provide Corporate Update

  3/2/2020

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2019 financial and operating results after the close of U.S. financial markets on Monday, March 9, 2020.

• Xenon Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

  2/14/2020

  BURNABY, British Columbia, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced public offering of 3,750,000 common shares, which initially closed on January 27, 2020, have exercised in full their option to purchase an additional 562,500 common shares at the public offering price of $16.00 per share, raising additional gross proceeds of $9.0 million and increasin

• Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares

  1/27/2020

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share

• Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares

  1/23/2020

  Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced the pricing of its underwritten public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share.

• Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares

  1/22/2020

  Xenon Pharmaceuticals Inc. announced that it has commenced an underwritten public offering of its common shares pursuant to its existing shelf registration statement.